Deepak Bhatt, MD
Interventional Cardiology · New York, NYNPI 1962515551
Payments from drug & device makers
Across 406 payments — averaging $10,124 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$1.7M
- Bristol Myers Squibb$1M
- AstraZeneca$250K
- Chiesi USA, Inc.$170K
- Cleerly, Inc.$150K
- Pfizer$97K
- plus $673K from 31 others
Across 87 payments — averaging $1631.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$62K
- Pfizer$45K
- Novartis Pharma AG$18K
- Sanofi-aventis U.S. LLC$7K
- Amgen$7K
- Regeneron$2K
- plus $1K from 1 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 23 | $1,740,967 |
| Bristol Myers Squibb | 181 | $1,030,125 |
| AstraZeneca | 4 | $249,826 |
| Chiesi USA, Inc. | 34 | $169,960 |
| Cleerly, Inc. | 7 | $149,823 |
| Pfizer | 5 | $96,900 |
| Amgen | 5 | $86,823 |
| Janssen Research & Development, LLC | 9 | $71,379 |
| Novartis Pharma AG | 7 | $60,588 |
| Boston Scientific | 2 | $57,420 |
| Astrazeneca AB | 2 | $55,120 |
| CSL Behring | 23 | $49,970 |
| Boehringer Ingelheim International GmbH | 21 | $38,509 |
| Eli Lilly | 11 | $36,336 |
| Sanofi US Services Inc. | 9 | $33,749 |
| Novo Nordisk AS | 8 | $31,656 |
| Boehringer Ingelheim Norway KS | 1 | $31,170 |
| Bayer | 8 | $22,138 |
| BTG International Inc. | 1 | $16,200 |
| Contego Medical, Inc | 1 | $12,013 |
| Boehringer Ingelheim | 7 | $11,938 |
| Astrazeneca UK Limited | 5 | $11,025 |
| GSK | 8 | $11,000 |
| Alnylam Pharmaceuticals Inc. | 2 | $6,533 |
| Boehringer Ingelheim RCV GmbH & Co KG | 1 | $5,565 |
| Corcept Therapeutics | 1 | $5,100 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $3,540 |
| Merck | 2 | $3,076 |
| Atricure, Inc. | 4 | $2,500 |
| Philips North America LLC | 1 | $2,085 |
| Daiichi Sankyo Inc. | 2 | $2,000 |
| F. Hoffmann-la Roche AG | 1 | $1,700 |
| Sanofi-aventis U.S. LLC | 4 | $1,500 |
| Medtronic | 2 | $795 |
| Regeneron | 1 | $765 |
| Cvrx, Inc. | 1 | $207 |
| Novartis | 1 | $149 |
How this compares
$4,110,148 in reported general payments places this provider in the 95th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in New York
- Martin LeonNew York$13.5M
- Susheel KodaliNew York$6M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
- George DangasNew York$2.6M
- Prakash KrishnanNew York$2M
- Ajay KirtaneNew York$1.8M
- Shing-Chiu WongNew York$1.5M
- Anvar BabaevNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.